secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2026-08-06T20:11:30+00:00
Accession:  0001104659-26-092005
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q2 revenue $15.7M (+16% YoY); lowers FY2026 revenue guidance to $58-60M
----------------------------------------------------------------------------

- Net loss $14.0M ($0.53/share) vs $14.7M ($0.57) in Q2 2025; cash $64.6M.
- U.S. revenue $14.8M (+21% YoY) on 466 units; active implanting centers grew to 258.
- Humana issued Medicare Advantage coverage policy for Barostim, effective May 1, 2026.
- FY2026 guidance: total revenue $58-60M, gross margin 86-87%, operating expenses $99-101M.
- Q3 2026 revenue expected between $13.5M and $14.5M; cites sales territory and payer headwinds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465926092005/0001104659-26-092005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465926092005/tm2622361d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-092005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer